Advancements in the field of biomedicine, including the control of infectious diseases through antibiotics and vaccination practices and the prevention of chronic disorders, have led to reduced mortality, increased life expectancy and, as such, growth of the older population. Ageing is accompanied by profound morphological and physiological alterations. In particular, the immune system undergoes a complex series of remodeling/restructuring events, involving almost all compartments - both the innate and the adaptive system. This process is termed immunosenescence or immune dysregulation and, basically, includes 3 events: a reduction in immune response, an increase in the inflammatory and oxidation background (inflammaging and oxi-inflammaging), and a production of autoantibodies. While there is an increase in autoimmunity in the elderly, this does not always translate into an increase in autoimmune diseases, which represent an important cause of morbidity and mortality and affect 5-10% of the world population. Each disease involves a specific age group. Generally speaking, most autoimmune diseases have a decreased peak age of onset, except for very few diseases such as giant cell arteritis and primary biliary cirrhosis, which are more prevalent among the elderly, or inflammatory bowel disease, which has 2 peaks of onset, the first one in young subjects and the other in those older than 60 years. Autoimmune disorders in the elderly have unique clinical presentations, and insidious and atypical symptoms may constitute a challenge for the physician. They are generally milder than in adults and can be controlled by a proper therapeutic treatment. However, despite advancements both in basic and clinical sciences, further studies and investigations are warranted and should be carried out in order to dissect the molecular framework induced by ageing.

1.
Smith M: Review lectures on senescence. I. The causes of aging. Proc R Soc Lond 1962;B157:115-127.
2.
Ferrucci L, Giallauria F, Guralnik JM: Epidemiology of aging. Radiol Clin North Am 2008;46:643-652.
3.
Freundlich B, Altman C, Snadorfi N, Greenberg M, Tomaszewski J: A profile of symptomatic patients with silicone breast implants: a Sjogrens-like syndrome. Semin Arthritis Rheum 1994;24:44-53.
4.
Stout MB, Justice JN, Nicklas BJ, Kirkland JL: Physiological aging: links among adipose tissue dysfunction, diabetes, and frailty. Physiology 2016;32:9-19.
5.
Brown-Borg HM, Borg KE, Meliska CJ, Bartke A: Dwarf mice and the ageing process. Nature 1996;384:33.
6.
Jin K: Modern biological theories of aging. Aging Dis 2010;1:72-74.
7.
Tosato M, Zamboni V, Ferrini A, Cesari M: The aging process and potential interventions to extend life expectancy. Clin Interv Aging 2007;2:401-412.
8.
Coppé J-P, Desprez P-Y, Krtolica A, Campisi J: The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol Mech Dis 2010;5:99-118.
9.
Castelo-Branco C, Soveral I: The immune system and aging: a review. Gynecol Endocrinol 2013;30:16-22.
10.
Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S: Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007;128:92-105.
11.
De la Fuente M, Miquel J: An update of the oxidation-inflammation theory of aging: the involvement of the immune system in oxi-inflamm-aging. Curr Pharm Des 2009;15:3003-3026.
12.
Ramos-Casals M, García-Carrasco M, Brito MP, López-Soto A, Font J: Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus 2003;12:341-355.
13.
Lindstrom TM, Robinson WH: Rheumatoid arthritis: a role for immunosenescence? J Am Geriatr Soc 2010;58:1565-1575.
14.
Aw D, Palmer DB: The origin and implication of thymic involution. Aging Dis 2011;2:437-443.
15.
Pfister G: Naive T cells in the elderly: are they still there? Ann NY Acad Sci 2006;1067:152-157.
16.
Sempowski GD, Hale LP, Sundy JS, Massey JM, Koup RA, Douek DC, Patel DD, Haynes BF: Leukemia inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy. J Immunol 2000;164:2180-2187.
17.
Pereira BI, Akbar AN: Convergence of innate and adaptive immunity during human aging. Front Immunol 2016;7:445.
18.
Xia J, Wang H, Guo J, Zhang Z, Coder B, Su DM: Age-related disruption of steady-state thymic medulla provokes autoimmune phenotype via perturbing negative selection. Aging Dis 2012;3:248-259.
19.
Ponnappan S, Ponnappan U: Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal 2011;14:1551-1585.
20.
Goronzy JJ, Weyand CM: Ageing, autoimmunity and arthritis: T-cell senescence and contraction of T-cell repertoire diversity - catalysts of autoimmunity and chronic inflammation. Arthritis Res Ther 2003;5:225-234.
21.
Sansoni P, Vescovini R, Fagnoni F, Biasini C, Zanni F, Zanlari L, Telera A, Lucchini G, Passeri G, Monti D, Franceschi C, Passeri M: The immune system in extreme longevity. Exp Gerontol 2008;43:61-65.
22.
Weyand CM, Fulbright JW, Goronzy JJ: Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol 2003;38:833-841.
23.
Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K: The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp 2015;63:435-449.
24.
Mellanby RJ, Thomas DC, Lamb J: Role of regulatory T-cells in autoimmunity. Clin Sci (London) 2009;116:639-649.
25.
Mehr R, Melamed D: Reversing B cell aging. Aging 2011;3:438-443.
26.
Szabo P, Shen S, Telford W, Weksler ME: Impaired rearrangement of IgH V to DJ segments in bone marrow Pro-B cells from old mice. Cell Immunol 2003;222:78-87.
27.
Frasca D, Riley RL, Blomberg BB: Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin Immunol 2005;17:378-384.
28.
Weiskopf D, Weinberger B, Grubeck-Loebenstein B: The aging of the immune system. Transplant Int 2009;22:1041-1050.
29.
Duggal NA, Upton J, Phillips AC, Sapey E, Lord JM: An age-related numerical and functional deficit in CD19+CD24hiCD38hiB cells is associated with an increase in systemic autoimmunity. Aging Cell 2013;12:873-881.
30.
Naradikian MS, Hao Y, Cancro MP: Age-associated B cells: key mediators of both protective and autoreactive humoral responses. Immunol Rev 2015;269:118-129.
31.
Vadasz Z, Haj T, Kessel A, Toubi E: Age-related autoimmunity. BMC Med 2013;11.
32.
Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW, Marrack P: Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c+ B-cell population is important for the development of autoimmunity. Blood 2011;118:1305-1315.
33.
Hazeldine J, Lord JM: The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev 2013;12:1069-1078.
34.
Montoya-Ortiz G: Immunosenescence, aging, and systemic lupus erythematous. Autoimmune Dis 2013;2013:1-15.
35.
Linehan E, Fitzgerald D: Ageing and the immune system: focus on macrophages. Eur J Microbiol Immunol 2015;5:14-24.
36.
Fortin CF, McDonald PP, Lesur O, Fülöp T: Aging and neutrophils: there is still much to do. Rejuvenation Res 2008;11:873-882.
37.
Grolleau-Julius A, Ray D, Yung RL: The role of epigenetics in aging and autoimmunity. Clin Rev Allergy Immunol 2009;39:42-50.
38.
Ramos-Casals M, Brito-Zerón P, Kostov B, Sisó-Almirall A, Bosch X, Buss D, Trilla A, Stone JH, Khamashta MA, Shoenfeld Y: Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. Autoimmun Rev 2015;14:670-679.
39.
Berti A, Campochiaro C, Cavalli G, Pepe G, Praderio L, Sabbadini MG, Dagna L: Giant cell arteritis restricted to the limb arteries: an overlooked clinical entity. Autoimmun Rev 2015;14:352-357.
40.
Brinks R, Hoyer A, Weber S, Fischer-Betz R, Sander O, Richter JG, Chehab G, Schneider M: Age-specific and sex-specific incidence of systemic lupus erythematosus: an estimate from cross-sectional claims data of 2.3 million people in the German statutory health insurance 2002. Lupus Sci Med 2016;3: e000181.
41.
Symmons D: The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002;41:793-800.
42.
Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L: The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014;73:1316-1322.
43.
Ahmed AR, Shetty S: A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev 2015;14:323-331.
44.
Phillips LH: The Epidemiology of myasthenia gravis. Ann NY Acad Sci 2003;998:407-412.
45.
Pekmezovic T, Lavrnic D, Jarebinski M, Apostolski S: Epidemiology of myasthenia gravis (in Serbian). Srp Arh Celok Lek 2006;134:453-456.
46.
McLeod DSA, Cooper DS: The incidence and prevalence of thyroid autoimmunity. Endocrine 2012;42:252-265.
47.
Alonso A, Hernan MA: Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129-135.
48.
Barnes J, Mayes MD: Epidemiology of systemic sclerosis. Curr Opin Rheumatol 2012;24:165-170.
49.
Ananthakrishnan AN: Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015;12:205-217.
50.
Mousa HS, Carbone M, Malinverno F, Ronca V, Gershwin ME, Invernizzi P: Novel therapeutics for primary biliary cholangitis: toward a disease-stage-based approach. Autoimmun Rev 2016;15:870-876.
51.
Ramos-Casals M, Brito-Zerón P, López-Soto A: Autoimmune diseases in the elderly: systemic lupus erythematosus and Sjögren's syndrome. Aging Health 2008;4:389-397.
52.
Giunta S: Is inflammaging an auto(innate)immunity subclinical syndrome? Immunity Ageing 2006;3:12.
53.
Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Lofgren S, Nilsson BO, Ernerudh J, Pawelec G, Johansson B: An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 2005;60:556-565.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.